ATE406178T1 - Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen - Google Patents

Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen

Info

Publication number
ATE406178T1
ATE406178T1 AT98960189T AT98960189T ATE406178T1 AT E406178 T1 ATE406178 T1 AT E406178T1 AT 98960189 T AT98960189 T AT 98960189T AT 98960189 T AT98960189 T AT 98960189T AT E406178 T1 ATE406178 T1 AT E406178T1
Authority
AT
Austria
Prior art keywords
presenting cells
depupperation
immunoreactivity
antigen
inhibition
Prior art date
Application number
AT98960189T
Other languages
English (en)
Inventor
Warren Shlomchik
Mark Shlomchik
Stephen Emerson
Original Assignee
Univ Pennsylvania
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Univ Yale filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE406178T1 publication Critical patent/ATE406178T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Animal Husbandry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98960189T 1997-11-12 1998-11-12 Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen ATE406178T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6519897P 1997-11-12 1997-11-12

Publications (1)

Publication Number Publication Date
ATE406178T1 true ATE406178T1 (de) 2008-09-15

Family

ID=22061000

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98960189T ATE406178T1 (de) 1997-11-12 1998-11-12 Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen

Country Status (6)

Country Link
US (1) US7288255B1 (de)
EP (1) EP1028754B1 (de)
AT (1) ATE406178T1 (de)
AU (1) AU754764B2 (de)
DE (1) DE69839943D1 (de)
WO (1) WO1999024078A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2324199A1 (en) 2000-10-25 2002-04-25 Vasogen Ireland Limited Chronic lymphocytic leukemia treatment
AU2002218019A1 (en) * 2000-11-03 2002-05-15 Nexell Therapeutics Inc. Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells
BR112017021536A2 (pt) 2015-04-06 2018-07-03 Harvard College composições e métodos para o condicionamento não mieloablativo
EA039364B1 (ru) * 2015-10-09 2022-01-18 Президент Энд Феллоус Оф Гарвард Колледж Композиции и способы для немиелоаблативного кондиционирования
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3765044A4 (de) 2018-03-12 2021-12-08 Medeor Therapeutics, Inc. Verfahren zur behandlung von nichtkanzerösen erkrankungen unter verwendung von hämatopoetischen zellen
US10842821B2 (en) 2018-04-05 2020-11-24 Medeor Therapeutics, Inc. Cellular compositions derived from prior organ donors and methods of manufacture and use thereof
US10881692B2 (en) 2018-04-05 2021-01-05 Medeor Therapeutics, Inc. Compositions for establishing mixed chimerism and methods of manufacture thereof
US11435350B2 (en) 2018-09-18 2022-09-06 Medeor Therapeutics, Inc. Methods of analysis of blood from deceased donors
US11813376B2 (en) 2018-09-18 2023-11-14 Medeor Therapeutics, Inc. Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239062A (en) * 1986-03-20 1993-08-24 Dana-Farber Cancer Institute, Inc. Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity
GB9117522D0 (en) * 1991-08-14 1991-10-02 Medical Res Council Ligands for dendritic cells, their uses and production

Also Published As

Publication number Publication date
EP1028754A1 (de) 2000-08-23
AU754764B2 (en) 2002-11-21
US7288255B1 (en) 2007-10-30
DE69839943D1 (de) 2008-10-09
AU1584999A (en) 1999-05-31
EP1028754B1 (de) 2008-08-27
EP1028754A4 (de) 2002-11-27
WO1999024078A1 (en) 1999-05-20

Similar Documents

Publication Publication Date Title
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
PT1032662E (pt) Metodos e composicoes para imunomodulacao.
IL189629A0 (en) Compositions containing human ctla-4 antibodies
NO982062D0 (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
PL328858A1 (en) Immunogenous peptides
BR0011000A (pt) Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico
DE69435303D1 (de) Er behandlung von krankheiten bei denen eine cytok
SE8902532L (sv) Bestaemning av plasmaproteiner
ATE406178T1 (de) Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
AR016295A1 (es) Antigeno de superficies y proteinas utiles de composiciones para el diagnostico y prevencion de la enfermedad de lyme
DE69732709D1 (de) Expressionsblockierung von virulenten faktoren in s. aureus
PT845998E (pt) Medicamentos para imunoterapia contendo anticorpos que reconhecem de forma especifica o antigenio mhcii de um paciente a ser tratado
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
HUP0001458A2 (hu) Specifikus hasnyálmirigy lipáz inhibitor hatású peptidek, ezeket tartalmazó gyógyszerkészítmények és diagnosztikai reagensek, valamint ezek alkalmazása
NO963487L (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
HK1071079A1 (en) Use of soluble fgl2 as an immunosuppressant
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
DE69636041D1 (de) Nachweis von brusttumorvirus-artigen sequenzen in brustkrebs bei menschen
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
WO1998051782A3 (en) Human 3-hydroxyisobutyryl-coenzyme a hydrolase
ATE435284T1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
WO1999050671A3 (en) Toso as a target for drug screening
DE50207168D1 (de) Kombinationspräparat zur Therapie von immunologischen Erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties